Pipeline & Products
TaiMed's portfolio spans an FDA-approved HIV therapy, clinical-stage long-acting antibody programs, and preclinical CD4-targeted research. Each program builds on a common foundation in CD4 biology while addressing a different stage of therapeutic innovation.
Product Discovery Pre-clinical Studies Phase I Studies Phase II Studies Phase III Studies BLA / MAA Market
產品Trogarzo® IV Discovery
 
 Pre-clinical Studies
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market
 
Role: Clinical and commercial foundation for TaiMed's CD4-targeted approach.

 
產品 Discovery Pre-clinical Studies Phase I Studies Phase II Studies Phase III Studies BLA / MAA Market
TMB-365 and TMB-380 combination Discovery
 
 Pre-clinical Studie
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market
 
Role: Lead clinical program; complete investigational long-acting dual-antibody regimen.

 
Product Discovery Pre-clinical Studies Phase I Studies Phase II Studies Phase III Studies BLA / MAA Market
產品TMB-365 Discovery
 
 Pre-clinical Studies
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market
 
Role: Next-generation CD4-targeted antibody used in TMB-365/380 and being considered for additional future combinations.

 
Product Discovery Pre-clinical Studies Phase I Studies Phase II Studies Phase III Studies BLA / MAA Market
Antibody-Drug Conjugates, ADCs  Discovery
 
 Pre-clinical Studies
 
 Phase I Studies
 
 Phase II Studies
 
 Phase III Studies
 
 BLA / MAA
 
 Market
 
Role: Targeted delivery research directed at the latent HIV reservoir.